

CENTERS FOR DISEASE CONTROL AND PREVENTION
NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH)
ADVISORY BOARD ON RADIATION AND WORKER HEALTH (ABRWH)
MEETING #166

THURSDAY, JUNE 18, 2026

The meeting convened at 11:00 a.m. Eastern Daylight Time (EDT)

Dr. Henry Anderson, Chair, presiding.

Vet Reporting
Certified Court Reporters
PO Box 72314
Marietta, GA 30007
678-646-5330 ext. 514
reporter@vetreporting.com

Members Present:

Henry Anderson, Chair
Josie Beach, Member
Frazier Bronson, Member
Bradley Clawson, Member
Arthur Frank, Member
James Lockey, Member
Nicole Martinez, Member
David Pompa, Member
Michael Schmoldt, Member
Kenneth Silver, Member
Faye Vlieger, Member
Paul Ziemer, Member

Registered Participants:

Rashaun Roberts, Designated Federal Officer
Nancy Adams, NIOSH Contractor
Bob Barton, SC&A
Kathy Behling, SC&A
Ron Buchanan, SC&A
Joe Fitzgerald, SC&A
Rose Gogliotti, SC&A
Malia Holzberger, Department of Health and Human Services (HHS)
Charles Nelson, NIOSH
Steve Ostrow, SC&A

Registered Participants Continued:

Brant Ulsh, NIOSH

Registered Members of the Public:

Deborah Jordan

Brenda Pigg

TABLE OF CONTENTS

Advisory Board on Radiation and Worker Health (ABRWH) Meeting #166	1
Proceedings	5
Welcome	5
Roll Call	6
Program Update	10
Public Comments	17
Plans for the August Board Meeting	18

PROCEEDINGS

(11:00 a.m. EDT)

WELCOME

DR. ROBERTS: I do have 11:00 a.m. Eastern, so I will go ahead and get it started. First of all, good morning. I'm Rashaun Roberts, and I am the designated federal officer for the Advisory Board on Radiation and Worker Health. And this is the Board's 166th meeting.

The primary purpose of this meeting is to prepare for the full Board meeting that's been scheduled for August 26th through 27th of this year. Although there are a few other items, namely updates on today's agenda. The agenda is posted on the NIOSH website. There is a schedule of Board meetings provided on that site, and you can access the agenda for today under the June 2026 tab.

I do want to add that I did receive several comments from petitioners, survivors, and others that I will enter into the public record today after the work group and subcommittee update agenda items. The comments and the agenda were provided to all Board members prior to today's meeting.

As you all may know, this meeting is being conducted by telephone only. In order to keep -- okay. I'm hearing somebody who continues to be off mute. Please mute your phone. In order to keep the meeting moving forward without interruptions, I do ask each of you to please mute your phone unless you're a Board member or staff member and you need to speak. If you don't have a mute button, press star six to mute. If you need to take yourself off, press star six again.

And also, because we're unable to see each other for this meeting, please identify yourself before your comments or your questions. I also ask that you please do not put this meeting on hold at any time and -- because we've discovered that we're unable to continue the meeting if someone places it on hold. So, again, please periodically check your phone to ensure that you haven't inadvertently come off mute or that you haven't placed the call on hold.

So, before I start the roll call today, I do want to share that one of our members, Loretta Valerio, made a decision to retire from the Board effective June 6th, so she won't be included in the roll call today or moving forward. The Board has developed a tribute, which will be shared later in this meeting.

So, with that said, let me move into roll call now. As the Board won't be discussion -- discussing issues beyond those that are a -- more administrative, Board members and others just need to indicate their presence for this meeting. For everyone other than the Board, please speak as clearly as possible when you state your name so that the transcript and the minutes reflect attendance accurately.

ROLL CALL

So, starting with the Board members in alphabetical order, is Anderson present?

CHAIR ANDERSON: Present.

DR. ROBERTS: Beach?

MEMBER BEACH: I'm here.

DR. ROBERTS: Bronson? Okay. Not hearing Bronson, Clawson?

MEMBER CLAWSON: I'm here.

DR. ROBERTS: Frank?

MEMBER FRANK: Here.

DR. ROBERTS: Lockey?

MEMBER LOCKEY: Here.

DR. ROBERTS: Martinez?

MEMBER MARTINEZ: Here.

DR. ROBERTS: Pompa?

MEMBER POMPA: I'm here.

DR. ROBERTS: Schmoldt? Is Schmoldt here? Okay. It sounds like someone's off mute. Can you put yourself on --

MEMBER BRONSON: Yeah, this is --

DR. ROBERTS: -- on mute? Okay. Go ahead.

MEMBER BRONSON: This is Frazier Bronson. I'm here.

DR. ROBERTS: Oh, great. Thanks, Frazier. Okay. Schmoldt? Okay. Not hearing Schmoldt.

MEMBER SILVER: This is Ken Silver. I was cut off, but I'm back. Hi.

DR. ROBERTS: Hi. Great. Thank you. Vlieger?

MEMBER VLIEGER: Here.

DR. ROBERTS: Ziemer?

MEMBER ZIEMER: I'm here.

DR. ROBERTS: And I'm circling back to Schmoldt. Are you here? Okay, okay. I don't hear him, but we do have a quorum, so we can proceed.

So, anyone with DCAS/Oak Ridge Associated Universities (ORAU) present?

DR. NELSON: Yeah, this is Charles Nelson. I'm present.

DR. ULSH: And this is Brant Ulsh, I'm also here (indiscernible).

(Whereupon, an attendee speaks off mute.)

DR. ROBERTS: Okay. Is someone off mute? Please mute your phone.

Okay. Anyone else for DCAS/ORAU?

MEMBER SCHMOLDT: Mike Schmoldt here. I just got back on.

DR. ROBERTS: Okay. Thanks, Mike. Okay.

Anyone else for DCAS/ORAU? Okay. Hearing none, SC&A?

MR. BARTON: Oh. Bob Barton, present.

DR. ROBERTS: Okay.

MS. BEHLING: Kathy Behling.

DR. BUCHANAN: Ron Buchanan.

MS. GOGLIOTTI: Rose Gogliotti.

MR. FITZGERALD: Joe Fitzgerald.

DR. ROBERTS: Okay. Anyone else for SC&A?

DR. OSTROW: Steve Ostrow?

DR. ROBERTS: Anyone else, SC&A? If not, HHS and contractors.

MS. HOLZBERGER: Malia Holzberger, HHS/OGC.

MS. ADAMS: Nancy Adams, NIOSH contractor.

DR. ROBERTS: Anyone from the DOL or DOE, other departments?

Hearing none, are there any members of the public on who would like to register their attendance?

MS. JORDAN: Deborah Jordan.

DR. ROBERTS: I'm sorry, could you repeat that?

MS. JORDAN: Deborah Jordan, J-O-R-D-A-N.

DR. ROBERTS: Okay. Thank you so much.

MS. JORDAN: Thank you.

DR. ROBERTS: Welcome.

Anyone else?

MS. PIGG: Brenda -- Brenda Pigg, P-I-G-G.

DR. ROBERTS: Okay. Thank you. Anyone else?

Okay. So, thank you so much to everyone, and welcome to the members of the public who are on today. So, again, before we move over -- move into the agenda and I hand the floor over to -- to Andy, the Board chair, please be sure to periodically check your phone, make sure that you're on mute. Again, if you don't have a mute button, press star six to unmute and press star six to take yourself off. Also, please don't put this -- this call on hold at any time because it disrupts the meeting, and it can't continue in that case.

Okay. So, with that, I will turn the floor over to Dr. Henry Anderson to lead the agenda. Andy?

CHAIR ANDERSON: Thanks a lot, Rashaun. I want to welcome everybody as well. And Rashaun and I have been busy over the black few weeks of getting the various work groups and subcommittees to be populated and a few new chairs appointed. And there's also been activity of two or more of the work groups and subcommittees. So, we really -- I'm pleased to see that we're beginning to get back on track with the full Board activity and have a meeting coming up.

So, with that, I'd like to have a program update from Chuck.

PROGRAM UPDATE

DR. NELSON: Okay. Thank you, Dr. Anderson. Can everybody hear me okay?

CHAIR ANDERSON: Yes.

DR. NELSON: Okay. I went off speaker, so maybe it comes through more clearly. Okay. Lori Marion-Moss is out today and next week she's on vacation, so I'm going to cover the program update for her. First topic is IT. She wanted to let everybody know access to the ORAU system continues through CyberArk only. Users needing support with the resource database or the board review system should contact NOCTSupport@ORAUcoc.org if they have any issues. So, CyberArk and ORAU are separate systems, any CyberArk updates and cyber -- cyber security updates in the planning and will be communicated before any changes occur.

So, update on DCAS staff: The DCAS director position closed in May, and the next steps are pending. So, I think they're maybe starting the interview stage for that. Deputy director LaVon Rutherford will retire this year on August 31st. He reminds that of us -- that to us daily, if not more often. Dose reconstructions and SEC petitions remain our top priorities until these positions are filled.

Next up is a contract update. Approval of the dose reconstruction recompetes contract has been delayed by policy changes. A six-month extension will be used, if necessary, to keep that contract going. With regard to dose reconstructions, due to our lower health physicist staffing levels, leave, and SEC workload, we have a little bit of a backlog, but we continue to

manage that as we go along.

And last -- well, yeah. Lastly, for outreach, NIOSH participated in joint outreach events in Aiken, South Carolina on April 22nd, Las Vegas on May 20th. We have a couple upcoming events. We have Oak Ridge June 30th and Los Alamos August 12th, and they're going to tag that trip. They're going to add Sandia National Lab, likely the 13th for that. And NIOSH has been approved to support these events.

And other than that, we're preparing meeting materials and travel approval for the August Board meeting. So, Dr. Anderson, that's all I have for a program update.

DR. ROBERTS: Andy, --

CHAIR ANDERSON: -- thank you. Can you hear me now?

DR. NELSON: I hear you now.

CHAIR ANDERSON: Okay. Chuck, are you doing a special exposure cohort status update?

DR. NELSON: I indeed am.

CHAIR ANDERSON: All right. You're on.

DR. NELSON: Okay. Good morning again, everyone. For the August '26 Advisory Board meeting, we don't anticipate that we'll be ready to present any new SEC petitions at that time. I do expect that work group chairs will provide updates today as needed when we get to that part of the agenda on current and ongoing SEC petitions that are with the Advisory Board. And that's really all I had for the update today. Are there any questions?

CHAIR ANDERSON: If people have questions, you'll have to speak up because we can't see any hands. So, take yourself off mute and speak and

we'll be all set. Not hearing any questions, --

MEMBER BEACH: I do have -- I do have one quick question, and it's back on the first presentation. When do you think the deputy director will be hired? Any idea?

DR. NELSON: I would not know that as of this point. It seems like the process is moving slower than it should, --

MEMBER BEACH: Okay.

DR. NELSON: -- unsurprisingly, but I don't have a good date for that, to be honest.

MEMBER BEACH: All right. Thanks.

DR. NELSON: All right.

CHAIR ANDERSON: Any other questions? Comments?

Updates From Work Groups and Subcommittees

CHAIR ANDERSON: Okay. Work groups and subcommittees that have met want to give a quick update?

MEMBER MARTINEZ: This is Nicole. I can give a quick update for Carborundum.

CHAIR ANDERSON: Great. Thank you.

MEMBER MARTINEZ: Great. We met two days ago for the first time in, I think, several years because of turnover on the Board and turnover within NIOSH, SC&A, etc. We had a great meeting, a lot of discussion getting our minds kind of wrapped back around the site and what's going on, what the timeline is. And so, we have a good path forward for that, I would say.

CHAIR ANDERSON: Thank you.

MEMBER CLAWSON: Henry, this is --

CHAIR ANDERSON: (Indiscernible) --

MEMBER CLAWSON: -- Brad.

CHAIR ANDERSON: Go ahead, Brad.

MEMBER CLAWSON: -- Brad. This is Brad Clawson. We had a work group with Hanford work group a little over a week ago. We've been waiting for five to six years for the co-exposure model to be able to be put together. They presented it to the work group. We had some discussion on it, and now it's in the hands of SC&A. They're going to go through it. We're -- we're waiting for an official report paper from NIOSH on what they did, and then SC&A will do the evaluation and get back with us on the work group.

With that one being said for Pinellas, I just received a -- a substantial amount of paperwork on it. The petitioners have been providing us with information a little bit more detailed into the specific issues that we've got. These are in the hands of SC&A, and SC&A will be doing the review and writing the report and getting back with us on that. And that's about all I can say for my work groups.

CHAIR ANDERSON: Okay. Thank you.

MEMBER BEACH: Henry, this is Josie Beach. I can report on the procedures subcommittee had a meeting and as usual, we closed out some items and are planning to present those close outs at the full Board meeting in August. Per usual, we are getting down to the last part of our list of items that we need to bring to the full Board at this time.

And on my work group LANL, we did have a meeting, and we had a vote within the work group to bring the issues and items to the full Board. So, we are on the agenda for August to discuss LANL and come to a decision within

the full Board. Thank you. That's all I have.

CHAIR ANDERSON: Thank you. I think that's the last meeting we had recently, if I remember correctly.

So, with that, as Rashaun said, the Board developed a tribute to Loretta R. Valerio, and I'd like to read that tribute into the record at this time. So, members of the Advisory Board on Radiation and Worker Health ("Board") wish to pay tribute to Loretta R. Valerio, who resigned June 6, 2026, from the Board after her long and distinguished tenure.

Loretta was appointed to the Board by President Barack Obama in 2012. Prior to serving on the Board, Loretta worked at Los Alamos National Laboratory and served as a caseworker for the Energy Employees Occupational Illness Compensation Program in Espanola, New Mexico. At Los Alamos, she was involved in the administration of safety-related operations, training, and communications at the site.

On August 27, 2007, then-New Mexico's governor Bill Richardson announced Loretta's appointment as director of the newly established Office of Nuclear Workers Advocacy, the only such office in the United States at the time. Her office was designed to act as a liaison between claimants and the Energy Employees Occupational Illness Compensation Resource Center, union officials, DOE contractors, retiree groups, and others to help lend guidance to those who encounter obstacles in the adjudication of their claims. Having been a caseworker, she understood the complex process of applying, documenting, and following up with the federal government when current or former workers, as well as eligible survivors of the Department of Energy workers file claims. Clients who dropped by her Santa Fe government office

were greeted by a life-size cardboard cutout figure of singer George Strait attired in his starched white shirt and cowboy hat, a gift from two grateful claimants who shared Loretta's appreciation for the country crooner.

Loretta was a hardworking and conscientious member of both the Board, subcommittees, the subcommittee for procedure reviews and subcommittee for dose reconstruction reviews. She also served on many Board working groups, including Metals and Controls, Argonne East, Ames, Blockson, and Lawrence Livermore National Lab, X-10, Y-12, Rocky Flats, and the surrogate data committee. She asked pertinent questions about worksite processes and National Institute for Occupational Safety and Health staff's dose reconstruction methods and questioned the Board's technical contractor staff during Board and working group meetings. The Board has benefitted from and will remember her soft-spoken manner and good company during meetings.

Inasmuch as Loretta has made significant contributions to the ongoing work to the Board during her 14 years in membership, we who remain as members of the Board, gratefully thank her for her service. She has served the Board and this country well. This tribute is hereby adopted by this 18th day of June 2026, at the 166th meeting of the Advisory Board on Radiation and Worker Health. Thank you.

Any other folks want to make a comment?

MEMBER SILVER: Yeah. This is Ken Silver. Loretta and I go way back, and I used to tell my students that you meet the best people if you get involved in worker health and safety issues. And I'll add that the closer you get to the grassroots, the real people, the family, the union officials, you met

even greater people. And I really value my friendship, many collegial interactions with Loretta. And around this time of the year, once I was in New Mexico at and Enterprise Rent-A-Car surprised me with a Camaro convertible, and she never stopped ribbing me about it. And, you know, we'd go to lunch in the beautiful New Mexico sun, and I promise we'll do that a couple of more times, Loretta. Thank you.

CHAIR ANDERSON: Thank you. Anyone else?

MEMBER BEACH: This is Josie. I just want to say she is going to be greatly missed on my subcommittees and work group meetings. I've developed a personal relationship with Loretta aside from Board work, so that will continue. And I tried my hardest to talk her out of it, but I knew she needed to -- to move on. So, she will be missed. Thanks.

CHAIR ANDERSON: Yeah, she was greatly appreciated. And as you heard, the number of the committees and activities, she never shirked and was really involved in nearly everything related to the Board and always had a valuable contribution to make to keeping things moving forward and keeping a civil discourse going on as well.

Any other comments?

MEMBER CLAWSON: This --

CHAIR ANDERSON: Go ahead.

MEMBER CLAWSON: This is Brad Clawson. (Audio distortion) thank Loretta for a lot of the years that she has been doing this and to the people that she has helped out through the years. She was much more than coworker or whatever else, she has become a part of our family. And we'll continue to always chat with one another. And I appreciate everything she's

done, and I understand fully the decision she's made, and I support her in that 100 percent. So grateful to have known her in my life. Thank you.

CHAIR ANDERSON: Thank you. Anyone else?

Okay. I'll turn it back over to Rashaun to give us an update, and we can talk about the plans for the August Board meeting and how it's progressing.

DR. ROBERTS: Okay. Thank you, Andy. Just a couple of items before I get to the plans for the August 2026 meeting. First of all, I did also want to express my appreciation for Loretta's membership on the -- on the Board and all the wonderful conscientious work that she did when she was part of the Board. And I just I really appreciate her kind heart, and she will sorely be missed. She was just a pleasure to -- to work with. So, I just wanted to add that for her.

PUBLIC COMMENTS

DR. ROBERTS: I did want to circle back and -- to the petitioner comments that I had mentioned at the beginning of the meeting. So, in advance of the meeting, I did receive statements from Deborah Jordan, Brenda Pigg, and Randall Jordan asking that the Board recommend the addition of a class to the Special Exposure Cohort for Petition 267, which is, I believe, United Nuclear Corp., the location being Hematite. Kyle Brewer and Terry Mousker (ph) also submitted a statement asking that the Board recommend the addition of a class to the SEC for Petition 226 and 227, respectively. But both also mentioned Hematite, Missouri, so I believe that their request is that the Board recommend an SEC addition for Petition 267 as

well. I do want to note that the petition is not with the Board at this time. It's still with NIOSH. Nonetheless, as I mentioned at the start of the meeting, I did forward all of the statements to the Board members in advance.

Okay. So, before, again, we get to the August 2026 Board meeting, I did want to let Board members know that we have been asked by the CDC Federal Advisory Committee Act Office to not schedule any meetings for the month of September. September is when all the FACA activities are basically getting wrapped up for the fiscal year. So, we've asked -- we've been asked not to schedule anything for that particular month.

PLANS FOR THE AUGUST BOARD MEETING

DR. ROBERTS: But as you know, we do have hopeful -- what will hopefully be a face-to-face meeting August 26th and 27th. I think I did let the Board members and staff know that we received agency approval for that meeting.

(Whereupon, an attendee speaks off mute.)

DR. ROBERTS: Whether -- okay, can people put their phone on mute, please? I heard some background noise.

So, tentatively the meeting will be face-to-face, and we're trying to get a meeting site for the Tampa, Florida area. However, that has not been firmly established. So, that is subject to change, but we are working on getting the paperwork in place for a meeting site in that general area, just FYI. And as I've said, I think I said this in the prior meeting, as soon as we get that paperwork in place, Zaida and/or I will be reaching out to let you know that things have been finalized and to work with the Board members to start

putting travel in place for that meeting.

If you recall, in April, I did sort of press us to sort of put together a sketch of what the agenda would look like for the August 26th-27th meeting. You know, since we've had meetings since that meeting, there may be adjustments that are needed to the agenda. So, I just want to take a few minutes to go through what I have and see, you know, if there are any tweaks that need to be made.

So, as per usual, we have the usual updates on the agenda. We have a NIOSH program update, an update from the Department of Labor, an update for -- for the Department of Energy, and with each running about 15 minutes apiece. There's an agenda item for the Carborundum work group that right now is -- has a 30-minute slot. I wanted to just inquire from you, Nicole, whether or not that's, you know, something we want to keep on the agenda for that amount of time.

MEMBER MARTINEZ: Hey, Rashaun. This is Nicole. No, I don't think so. I think I can do it in 5-10 minutes.

DR. ROBERTS: Okay. So, would this be more like a work group update is what you're thinking?

MEMBER MARTINEZ: Yeah.

DR. ROBERTS: This is --

MEMBER MARTINEZ: Yes, I think so.

DR. ROBERTS: Okay. So, --

MEMBER CLAWSON: (Indiscernible) --

DR. ROBERTS: -- no (indiscernible) --

MEMBER CLAWSON: Rashaun, Nicole, just one of the things about this,

Nicole, you're now bringing it before the full Board that (audio distortion) so I'm thinking we're going to get a fair amount of questions. That's why I thought we kind of put it for a half an hour, so that other members that aren't on the work group may be able to ask questions to get start getting themselves familiar with it. But that was just my opinion, though.

DR. ROBERTS: Okay. Nicole, what are your thoughts, Nicole? You know, it has --

MEMBER MARTINEZ: -- that's fine. I don't care.

DR. ROBERTS: Okay. So, -- so, we're thinking maybe a 15-minute presentation, probably with Q&A for another 15 minutes for that item?

MEMBER MARTINEZ: Sure.

DR. ROBERTS: Okay. And just to see, who would be presenting? I don't know, Bob on -- on behalf, would that be Amy?

MR. BARTON: Yes. Hopefully you can hear me. We can certainly report out on, you know, what recently happened two days ago. It might be beneficial for a short recanting of the -- not recanting. But -- but presenting, you know, a brief history of the Carborundum site. But at this point, the status going forward is that we're waiting on some items, TBD updates from NIOSH, so I'm not sure it's a great use of the Board's time to really go into any depth on it. So, I -- I'm sort of with Dr. Martinez and that we should definitely update the Board on what has occurred in that work group has been re-formed and went over a lot of the backstory on Tuesday, but there's nothing really to -- to vote on. So, again, I -- I just don't want to waste the - the Board's time.

DR. ROBERTS: Okay.

MR. BARTON: I don't know if Dr. --

MEMBER MARTINEZ: -- Nicole. I -- I think --

MR. BARTON: -- (indiscernible) --

MEMBER MARTINEZ: -- if we had just a short presentation on, kind of -
- I definitely don't think we need the full timeline. That's my -- my personal
view. I think more effective would be where we are now, maybe some
activities of the site, just kind of big picture what happened. We don't need
like year-by-year, I would say.

DR. ROBERTS: Okay.

MEMBER MARTINEZ: Bob, does that make sense?

MR. BARTON: Yeah. I think we can put together a few slides on,
basically, the status of that site discussion as it occurred --

MEMBER MARTINEZ: Yes.

MR. BARTON: -- on Tuesday, and I think that makes sense.

MEMBER MARTINEZ: Great.

DR. ROBERTS: Okay.

MEMBER MARTINEZ: And then our -- our work group was compiling
questions, and so maybe that offers the opportunity to answer those
questions for the full Board or something. But yeah, I -- I -- we can book 30
minutes, but I don't think it will take 30 minutes.

DR. ROBERTS: Okay. We'll just do 30 as a placeholder with, it sounds
like, SC&A doing a short -- a short presentation, perhaps doing some Q&A is
what -- what that sounds like. Okay, great.

Okay. Then next up, I do have an item for procedure review if -- the
typical 90 minutes. Josie, does that work?

MEMBER BEACH: I think it does work, but I'm going to defer to Kathy since she's putting together the slides for it.

Kathy, what do you think?

MS. BEHLING: Yes, 90 minutes should be fine. I have listed about six documents, and so, yeah, 90 minutes. I agree with that.

DR. ROBERTS: Okay.

MEMBER BEACH: Thank you.

DR. ROBERTS: Great. And then we do have the SEC issues update, which is allotted the typical 15 minutes. So, I assume that that -- that's okay. That's just a standard item.

I still do have an item, Andy, for special exposure cohort issues. I know that there were some questions that Bob had raised about that presentation. But -- but where are we with that? I have about an hour -- it looks like an hour and 15 minutes dedicated right now to that item.

MR. BARTON: Well, and this is Bob. I can comment on that. Andy can slap me down. Basically, what I -- I feel like the best use of time would be to update everyone on the path forward that is being undertaken as we speak, which is basically that compendium of previous SEC decisions. We can also provide a briefer presentation on what the general philosophy is for SEC evaluations if -- if the Board thinks it -- it will be helpful. And it might be, especially for the newer Board members. So, that -- that's what I would suggest is that, basically, a -- a very brief primer similar to what was presented at the SEC issues working meeting and then an update on the path forward decided from that meeting. That -- that's what I would suggest. I don't know, Andy, it's your show.

DR. ROBERTS: Andy, if you're on mute, we can't hear you.

CHAIR ANDERSON: Yeah. Okay. Sorry. That -- that's what I was thinking about. And we, I think, want to have some discussion of the group, but we aren't -- with the whole Board, but we aren't going to have a compendium together. It's really, I think, quite a bit of work, as we talked about it, Bob. And -- and there's just not time to get a draft or anything of this report, but I think it will be very helpful to -- I mean, there's been a lot of work done over the years with different groups and different individuals.

So, I think that's a good idea to pull that together, so we have somewhat of a background on what has been done. And -- and part of the discussion is we don't -- we -- we have tried to pay attention to precedents that were set with how things were done, but there have been changes in processes as we've gone forward. So, I think a summary that Bob pointed out is -- is what we can have. I don't know if we need a whole hour and a half, but we could get into a fairly in-depth discussion.

DR. ROBERTS: Okay. It's for an hour and 15 minutes, so how much time?

CHAIR ANDERSON: Hard to tell.

MR. BARTON: This is -- this is Bob. I think 45 minutes is max --

DR. ROBERTS: Okay.

MR. BARTON: -- for what we need at this point. I'd also add on to Andy's comments that -- well, this is a rather unique situation because while we're trying to put together the compendium of SEC decisions and the rationale, we're also going to be working with DCAS to make sure that we're all on board with what happened. So, this might be a longer process. And so,

certainly August is probably not feasible. Optimistically, December, we might have something altogether that we can present to the Board that would require 90 minutes or more, frankly.

DR. ROBERTS: Okay. All right. Well, then I'll change that to 45 minutes now. But I'll move on --

DR. ULSH: Rashaun? Rashaun?

DR. ROBERTS: Yeah, uh-huh?

DR. ULSH: This is Brant Ulsh for DCAS. I just wanted, before we move on away from the SEC issue, I -- I'm pretty sure I did not hear a request for DCAS to make any kind of a presentation, but of course, we'll be available to productively participate in the conversation. But is that -- you agree, Dr. Anderson?

CHAIR ANDERSON: I think so. Yeah.

DR. ULSH: Okay. All right. Thank you.

CHAIR ANDERSON: We certainly want you to -- I don't want it to just to be a one-sided presentation of kind of what SC&A has in their records. And so, there's often been discussions back and forth with some of the SEC, so it's important to have NIOSH's perspective on things or how things may have changed over the time. And a lot of the procedures that are being used have -- have evolved and become more sophisticated, I would say. And I think that would be the sort of thing you could comment on.

I was almost going to say when we were talking about Carborundum, we have not had many (indiscernible) of uranium processing plants SECs in a while. And so, the use of Carborundum, where it's almost all surrogate data but we haven't used or had much of a discussion on surrogate data for some

time in some of the other SECs. It's been more in the coming up with coworker/co-exposure models, which is a bit different than surrogate that use.

DR. ROBERTS: Okay. So, -- so, just to clarify you're -- you're saying that you're not looking for NIOSH to do a presentation, but possibly provide some kind of remarks or commentary?

CHAIR ANDERSON: Yeah, I -- I -- I think so. I think as Bob develops, what's going to go forward, I certainly want to offer NIOSH the -- or DCAS the opportunity to present on, you know, what -- what they've done for some of these or the evolution of -- of the SEC review process.

DR. ULSH: Okay. We'll -- we'll be there to -- to --

CHAIR ANDERSON: (Indiscernible) kind of SEC and dose -- go ahead. Go ahead.

DR. ULSH: Yeah. We'll definitely be there with full staff to represent the NIOSH perspective. I just wanted to make sure that you guys weren't requesting any kind of a formal presentation or anything.

CHAIR ANDERSON: No, I don't think so.

DR. ULSH: Okay. Thank you.

DR. ROBERTS: Let's get -- just sort of in that same vein, if we could just circle back to Carborundum for a moment, I just want to make sure that SC&A would be doing the presentation for that item, Nicole, or were you thinking that NIOSH would do something for that?

MEMBER MARTINEZ: Six of one, half a dozen of another. I don't think it -- it really -- they both presented very similarly, so I don't think it needs to be both. But I don't know. Y'all want to paper, rock, scissors for it?

DR. NELSON: Well, this is Charles, and I think we would prefer not

presenting. And like Bob said, you know, we don't want to use the Board's time with multiple presentations on this. It seems like it would just be a quick update --

DR. ROBERTS: Okay.

DR. NELSON: -- what I'm hearing.

MEMBER MARTINEZ: Yep, agree.

DR. ROBERTS: Okay, great. I just wanted to solidify that. Let's move on. And if people can, put their phones on mute, again.

For Pinellas Plant, there's a two-hour block for that, Brad, with you down, if you want to provide some kind of opening, Steve Ostrow, and Maddie Cook on that item.

MEMBER CLAWSON: Yeah. We want to kind of give a background, but I'm wondering about that with the information that we have (audio drop) lately.

DR. ROBERTS: Brad, you sound far away. I can barely hear you.

MEMBER CLAWSON: Sorry. Is this better?

DR. ROBERTS: Yeah. That's better.

MEMBER CLAWSON: Yeah. I'm just -- I'm wondering about -- about what we've -- we've -- we've -- in the last -- well, in the last day for me, we've received quite a bit more information on this. And I think that I was kind of hoping that SC&A was going to have a report by this time. But in speaking, I think that they've got to look at some of the information provided. I'd like to -- I'd like to I'd like to be able to give the opportunity to be able to discuss this, because this is starting to come before the full Board meeting.

Bob, as you mentioned here a week or so ago, that you didn't feel that

you were going to have a report ready; is that correct?

MR. BARTON: Yeah, I can update on that. The report is actually with our editing right now.

MEMBER CLAWSON: Okay.

MR. BARTON: We decided the best thing for the work group was to -- you know, this has been a developing discussion, obviously, with new materials that comes in almost weekly. So, like we did in the past with our interim reports, we're going to cut it off here. That is not to say that we're not going to evaluate new information going forward. But I do think that -- especially if we're going to be down in Tampa, that the petitioners really deserve a -- a -- an update presentation at least on where we are on all of these numerous issues and to let them know that we're still considering new information that -- that's kind of flowing in. So, --

MEMBER CLAWSON: Okay.

MR. BARTON: -- again, SC&A -- we made the call or I made the call that it would be more beneficial to the Board if we get a report out before the August meeting and then move forward based on that and the new information that you indicated. Anyway, that's --

MEMBER CLAWSON: (Indiscernible) --

MR. BARTON: -- where we're at. We can -- we can pull the report out of production if you really want the new --

MEMBER CLAWSON: No, --

MR. BARTON: -- information to be evaluated and included.

MEMBER CLAWSON: I -- if -- the information I had was just basically clarification to the information we (audio drop). So, that's kind of where I

was wondering in that. But no, I want to keep the report going and especially where we're going to be in Tampa. I want to be able to bring the discussion up to be able to -- be able to discuss it, especially with the people in there and the petitioner. So, I -- I think we'll just -- I think we'll just proceed on where we're going.

MR. BARTON: Yeah, I --

MEMBER CLAWSON: And then --

MR. BARTON: -- agree with that. I -- I think it's warranted at this time to have a significant presentation on this site because of the location where we're going. And there's been a substantial amount of documentation that's been submitted and evaluated. So, yeah, I -- I -- I don't think we should hold this up, but we will continue.

I mean, all these reports are always called drafts for a reason, because there's always -- always going to be new information that informs. And it sounds like the new information will inform the discussion, and it won't necessarily affect what our report will say, which again, we're hoping to get out at least --

MEMBER CLAWSON: Well, I just want --

MR. BARTON: -- you know, a week or two before the Board meeting.

MEMBER CLAWSON: Okay. Yeah. So, I'd like to be able to have you go over that report and then -- and go from there, open it up to some discussion and basically discuss where the issue is, what -- what the issues are that we're having and be able to respond to those. Like I say, though, there will be some new information that I know -- note you or NIOSH won't be able to really report to until you evaluate it. So, I -- yeah, we'll just proceed

ahead with that.

MR. BARTON: Okay. I think that's a --

MEMBER CLAWSON: (Indiscernible) --

MR. BARTON: -- reasonable and positive path forward.

DR. ULSH: Okay. This is Brant Ulsh. I just want to make sure I understand what -- what we're going to be covering about Pinellas in August. Are we going to cover the new material that was just submitted in the past couple of days, or is that -- we're going to put that off --

MEMBER CLAWSON: Why (indiscernible) --

DR. ULSH: -- the workers to talk about?

MEMBER CLAWSON: Actually, Brant, that -- this is just a clarification on information that was submitted earlier. Basically, what we're going to be discussing is the latest one that came out, and that is the white paper. This other information that is coming out in it is -- is just supporting what that white paper put out. So, it's really not new information. It's just clarifying information. So, that --

DR. ULSH: Okay. Well, I --

MEMBER CLAWSON: -- reviewing is her paper that she -- Dr. DeGarmo put out, but I call it a white paper.

DR. ULSH: Okay. So, the -- the submissions that she submitted in the past week, I understand you're saying that that goes along with her earlier white paper, but those submissions, both SC&A and NIOSH, you're -- you're requesting that we have those evaluated and be prepared to talk about them in August; is that correct?

MEMBER CLAWSON: Well, it would be nice, but I'm -- I'm not really

sure that you're going to be able to do that.

DR. ULSH: No, I'm --

MEMBER CLAWSON: -- look at it, Brant. And I'm going to be honest with you, because to me, what I've already read, this was -- this is just -- these have just been some submitted to us or just clarifying what was -- had been done earlier.

DR. ULSH: Well, we haven't really --

MEMBER CLAWSON: -- evaluation and so forth, so when we get to it -- you know what, we're going to -- I -- I -- if you can't talk to it at that time, you're not going to -- I understand. I'm not holding you to that. But we do need to be able to discuss the white paper.

DR. ULSH: Okay. If that's the expectation, we will be prepared to discuss the white paper.

MEMBER CLAWSON: Okay. Sounds good.

DR. ULSH: And Brad, are you -- are you requesting, like, a presentation from NIOSH, or? I mean, I guess if SC&A's presenting, I guess --

MEMBER CLAWSON: SC&A's going to do a presentation. If you feel that you need to, you know, I just need to know that up front.

DR. ULSH: Okay.

MEMBER CLAWSON: But, you know, it's -- I don't think -- you've already kind of put yours together. It's kind of in SC&A's hands at this time.

DR. ULSH: Okay.

MEMBER CLAWSON: Unless I -- unless I'm seeing it wrong, Brant.

DR. ULSH: Yeah. We'll talk about it over here, and if we -- if we want to give a presentation, we'll reach out to you and Rashaun and the other

members of the work group.

MEMBER CLAWSON: Okay. Okay.

DR. OSTROW: Hi. This is Steve Ostrow --

MR. BARTON: This is Bob. We had planned on presenting. So, you can -- you can -- we can work it out. You know, I think the -- the folks down there in Florida deserve, you know, a full recounting of where we are.

MEMBER CLAWSON: Okay.

DR. OSTROW: Hi, this is Steve Ostrow, --

CHAIR CLAWSON: Go ahead, Steve.

DR. OSTROW: -- just clarify briefly, because it's a little bit confusing if you're not familiar with this. Okay. The authorized petitioner representative came out with the so-called weight of evidence paper, which is about ten pages long on January 14th, from the central (audio drop).

MEMBER CLAWSON: Uh-huh.

DR. OSTROW: -- NIOSH (audio distortion) made a their response paper on March 25th. So, that came out already. SC&A has been working on a response paper, which is -- turned out to be longer than we expected. As Bob mentioned earlier, it's in the technical review stage of SC&A. And then, you know, it has to go to the various -- like, DOE and so forth before they can publish it, but we're sort of on schedule to having a paper out in a timely fashion before the August meeting. And in any event, we plan on having a slide presentation of our findings for the August meeting. That'll basically summarize everything that's (audio drop) important that we have in the paper. So, that's sort of the history of this. And it sounds reasonable to me that at the August meeting, NIOSH gives some presentation on their response

and -- if they want to, and SC&A will give a -- a presentation on its response paper.

The new -- the new stuff that we've been getting in from the -- from the authorized petitioner representatives has been coming in, like, you know, one or two documents at a time over the last week or two. And frankly, Brad's analysis, I think, is correct, that this was more of a clarification or amplification of what she submitted before, was not really new material. And a lot of it will probably be covered just (audio drop) course of that in the August presentation.

But I don't think that we or NIOSH probably have the time to, you know, respond explicitly to the new information that's come in, because this will keep on going also. So, rightly so. She may submit more next week and more the week after. So, at some point we have to have a -- you know, pen down sort of moment and actually write a paper. That's my feelings on it.

DR. ULSH: I agree whole- --

MEMBER CLAWSON: Okay. Well, I'm not --

DR. ULSH: -- heartedly with you. It's a constant stream of information coming in, and we just have to have, like you said, a pens-down moment where we can all speak to the information up to that point, but so we're not being obligated to do a rush presentation on the stuff that we get three days before the meeting, you know.

MEMBER CLAWSON: Right. And I understand that. And but you do also agree this is just basically clarification to the information that was sent before. That -- that's what I was -- what I was trying to put forth. But I agree 100 percent, we have to have a -- draw a line in the sand and put

together a report and go in there. And that's -- that's what I'd like on -- for this.

DR. ULSH: Okay.

MEMBER POMPA: Bradley, this is David Pompa. Can I ask a question, Bradley?

MEMBER CLAWSON: Sure.

CHAIR ANDERSON: Go ahead.

MEMBER POMPA: Okay. Just when we discussed Pinellas, it's very -- it is a very serious situation, will it be just the Board, SC&A and so forth, or there'll be an audience in the room?

MEMBER CLAWSON: It'll probably be -- there'll probably be people from Pinellas because that's -- that's why we're doing it in Tampa. We will have an audience there.

MEMBER POMPA: Okay. Okay. Thank you, Bradley.

MEMBER CLAWSON: Yep. Okay. So, --

CHAIR ANDERSON: Go ahead.

MEMBER CLAWSON: Go ahead, Andy. Well, I was just going to say --

CHAIR ANDERSON: -- no.

MEMBER CLAWSON: -- so, we -- we -- I agree with Bob, and we need to proceed forward. We'll plan on SC&A giving a report on -- on what they've got, and it's already going through editing. And as soon as it gets out, we would like it to come out to -- actually, it'd be the work group and the -- the full Board or whatever, so that they understand what we're discussing and where we're going. But that'll -- that's my feeling on the path forward that we should be able to go.

DR. ROBERTS: Okay, Brad, is the two-hour slot, is that enough time?

MEMBER CLAWSON: I think -- I think we're going to have -- I think that will be plenty of time.

DR. ROBERTS: Okay.

MEMBER CLAWSON: I think we're going to have quite a bit of discussion on it, so.

DR. ROBERTS: Okay. What --

MEMBER CLAWSON: I'm just -- I'm wanting -- I'm wanting to give us enough time, Rashaun, especially in the public setting like this.

DR. ROBERTS: Right.

MEMBER CLAWSON: The discussion seems to go a little bit more, especially where it's dealing with a facility in their area. I know that -- I know that they can't talk or anything else like that, but there's -- there's a lot more discussion that goes on, especially in these public meetings.

DR. ROBERTS: Right, right. Okay. So, we'll stick with the two hours. Following that I have the hour public comment period.

So, moving on, another agenda item is Los Alamos. And there is a four-hour block of time for Los Alamos. Josie, will that work for you?

MEMBER BEACH: Yeah, that seems like a lot, but I know it's -- it's going to come into -- a lot of discussion is going to come into that. And Bob, what do you think? That -- that's plenty of -- I believe.

MR. BARTON: Yes. That -- that'll be plenty of time. But as you indicated, there's a long history of discussions with this site. There's a lot of material going back and forth. And this ties back into the SEC issues, presentations that are going to occur. So, but four hours is plenty.

MEMBER BEACH: Yeah. Rashaun, there should be at least three presentations, NIOSH, SC&A, and I plan to do one also. We may have --

DR. ROBERTS: Okay. That's --

MEMBER BEACH: We may have the petitioner want to present also. I -- I'm going to reach out to him.

DR. ROBERTS: Okay. Thank you.

MEMBER BEACH: Okay.

DR. ROBERTS: Yeah. And that -- that would be optional to them. Okay, great. So, we'll stick with the four-hour slot.

And then Hanford, Brad, there's an hour on the schedule for Hanford. I don't know what -- what do you feel about that, and who would you like to present for that?

MEMBER CLAWSON: Well, with the presentation on that, we just -- we just barely got from -- I -- I'd like them -- I'd like them to bring -- I guess NIOSH is the one that did the last presentation to the Hanford work group. I want them to be able to bring that up. SC&A's not had enough time to be able to evaluate anything, nor do we have the documentation from NIOSH. I would like to -- I'd like to bring that one up -- bring it up for discussion, where we're at on it, and -- and go from there.

So, Brant, I would like -- I would like to have the presentation that you gave to the work group brought up and brought before the full Board. And then -- then we can discuss our path forward that we're going and go from there.

DR. ULSH: Okay. We're --

MEMBER CLAWSON: (Indiscernible) --

DR. ULSH: -- prepared to do that.

MEMBER CLAWSON: -- that.

DR. ULSH: And recall that when we -- when Alek gave our presentation, there were a couple of items that we expected to have finished imminently. So, we may be prepared to, you know, kind of update the presentation with those results too, if you like.

MEMBER CLAWSON: That -- that would be fine. And -- and then like I say, there's still a report that's due to SC&A and the work group of -- of the use that was -- justification in the use. And I -- I appreciate that. And we'll go from there. Yeah. You had a plutonium one that was in the process of being finished.

DR. ULSH: Right. All right. We'll be prepared --

MEMBER CLAWSON: Okay.

DR. ULSH: -- to give that presentation.

MEMBER CLAWSON: Okay.

DR. ROBERTS: Okay. So, okay. Does the hour work then?

MEMBER CLAWSON: Yes, that will --

DR. ROBERTS: Does it --

MEMBER CLAWSON: That'll be fine. That'll be -- that'll give us enough time to be able to discuss it, because this -- this all comes back to the use of surrogate data, the -- meeting the criteria for (audio distortion), I believe it is, and so forth, so there'll be a fair amount of discussion on that. And go from there. But I think the hour should be fine.

DR. ROBERTS: Okay, great. And then lastly, we have an hour allocated to a Board work session as per usual. So, those are all the agenda items I

had. Is there anything that's missing that -- that folks would like to add to the agenda? Okay. Well, hearing none --

MEMBER LOCKEY: -- Jim Lockey. One question. We're definitely going to have an in-person meeting though, correct?

DR. ROBERTS: No. And I would advise people to not start making arrangements or get it cemented in the mind that it's going to be face-to-face. We -- we still have to navigate the contract system in order to get the meeting site. It's tentatively face-to-face, possibly Tampa, although that is subject to change. So, hopefully --

CHAIR ANDERSON: We will definitely have a meeting, but it'll --

DR. ROBERTS: Yeah.

CHAIR ANDERSON: -- we may end up on Teams again. So, we will go through this, but face-to-face is a challenge.

DR. ROBERTS: Right.

MEMBER LOCKEY: Just Jim Lockey. I personally hope that doesn't happen. There's such a loss when that occurs with --

DR. ROBERTS: Yeah.

MEMBER LOCKEY: -- new members. It would be, I think, tragic not to have an in-person meeting. That's my personal feeling about that.

DR. ROBERTS: Thank you. I mean, we are really putting forward every effort to try to have it face-to-face and hoping that, you know, the administrative pieces fall into place so that we can go ahead and do this. But as soon as we have confirmation, you know, that the paperwork's in place, I will be reaching out and -- as well as Zaida to let you know. Zaida then will do the travel for you all.

Okay. Any other questions about that?

Okay. Back to you, Andy.

CHAIR ANDERSON: Thank you. Just one last thing. And this is back to the SEC issues. I don't know whether we need it or not, but there's always been questions on the timeliness (audio drop) about why we have these SECs and other decisions and we're going through new data coming in and all that. And many of the claimants want to know what's happening with the dose reconstructions during these periods. So, it might be helpful for some kind of a presentation on what's going on at the time of -- that, in fact, the dose reconstructions for sites that are still under consideration are, in fact, being done and moving forward. And then what happens if -- if new models come in to be used and things like that.

Since this is a -- a -- there's a public down there, I know that some of the questions that when I've been at the public meetings, people are wondering, well, why are you working on all of this, I have my application -- I have my documents in and does this mean. I just have to wait and wait. And I think the reality is they are moving forward with the data they have and the current processes. It's only if a subsequent decision is made different, then things get reworked rather than it all just kind of sits there waiting until a final decision is made. So, I don't -- I don't know if that something that would be worth having just a few minutes of a presentation from NIOSH to say how is the dose reconstructions going forward and what impact or how the -- does the deliberations on SECs and new models coming in and things like that interact with the ongoing work.

DR. ULSH: Okay. This is Brant Ulsh with NIOSH. I -- I hear what

you're saying --

CHAIR ANDERSON: (Indiscernible) --

DR. ULSH: -- and I think -- yeah. Well, I think that's a very good message for the public to hear, because I think that's not generally understood. And I agree with you, there's a lot of concern out there that while these SEC petitions go on ten years, their dose reconstructions are not sitting in a parking lot. And a lot of people think that that's the case. So, I think there's some value in that.

Rashaun, I guess we would have to put something like that -- make space for that in the agenda.

DR. ROBERTS: So, are we --

DR. ULSH: I don't think it necessarily has to be a long presentation.

DR. ROBERTS: So, are we talking about extending the time for the agenda item that already allocated to Special Exposure Cohort issues or adding --

CHAIR ANDERSON: I don't think we need a -- a -- overly comprehensive review, kind of a thing, but some kind of a summary. And I don't know. I was just now as we were going through all the others -- I think since the SEC issues will be in the public meeting earlier, that might be a time for ten minutes or 15 minutes type of presentation talking about that.

DR. ULSH: Yeah, I was thinking 15 minutes as well, Henry, when you were describing what you were interested in.

CHAIR ANDERSON: Yeah. Yeah.

DR. ULSH: Can we fit that in the existing 45 minutes for SEC issues, or do we need more than that for SEC issues?

CHAIR ANDERSON: I think we could probably fit it in.

DR. ULSH: Okay. All right. I think I understand --

MR. BARTON: Well, this -- this --

DR. ULSH: -- what you're asking.

MR. BARTON: -- is Bob. Just as a comment on this -- this discussion in particular, a lot of the concerns that -- very valid concerns that the public have are sort of addressed in various parts of this meeting agenda, including the program update.

(Whereupon, an attendee speaks off mute.)

MR. BARTON: -- how many dosing instructions are being performed, and we've had --

DR. ROBERTS: Okay. Somebody is off mute, please put your phone on mute, please.

MR. BARTON: I keep thinking I'm hearing myself.

MEMBER BEACH: Yeah.

DR. ROBERTS: Yeah. I'm hearing someone talk.

(Whereupon, an attendee continues to speak off mute.)

DR. ROBERTS: Hello?

UNIDENTIFIED SPEAKER: -- when somebody who usually emphasizes reasoned arguments, writing, prepared remarks from the microphone, --

CHAIR ANDERSON: Somebody's not on mute.

UNIDENTIFIED SPEAKER: -- takes the pitch up a few notches like Drew did, it's telling us something. So, if he feels that way, there are probably --

DR. ROBERTS: Hello? Hello? Hello?

UNIDENTIFIED SPEAKER: -- concerned talking about delayed dose

reconstructions in the interim, but I would urge a presentation based on numbers of dose reconstruction.

DR. ROBERTS: Okay. Okay. Andy, was -- so we're going to --
(Whereupon, the unidentified speaker continues speaking off mute.)

DR. ROBERTS: -- so Bob's point is that that might be addressed in various other updates.

CHAIR ANDERSON: Yeah, (indiscernible) --

DR. ROBERTS: -- meeting --

UNIDENTIFIED SPEAKER: -- but --

CHAIR ANDERSON: Yeah, I just want someone --

UNIDENTIFIED SPEAKER: -- numbers --

CHAIR ANDERSON: -- doing their presentations, just keep that in mind and maybe make mention of it. I don't know whether we need a separate presentation or not. But I just thought -- hopefully, it'll be all covered, but I don't want the people to be left with not understanding what's going on.

DR. ROBERTS: Okay. Well, --

MR. BARTON: I think, at least from our side, the presentations we'll be giving can emphasize that point. And also, the program updates and such have -- generally have those numbers on the number of DRs completed and also --

CHAIR ANDERSON: Yeah.

MR. BARTON: -- whether they're up to speed. Because even during the cybersecurity updates, which, you know, severely hindered the entire process, you know, DCAS's focus was on making sure that, so to speak, those -- those DRs are not -- dose reconstructions are not sitting in a locker somewhere in a

parking lot. So, we can --

CHAIR ANDERSON: Yeah.

MR. BARTON: -- emphasize that certainly.

CHAIR ANDERSON: That's what I would recommend for the group that's going to be presenting. Keep that in mind and, you know, just build it into what -- what you say.

DR. ULSH: Okay. So, no separate -- sorry, Brant Ulsh again. So, no separate presentation under the SEC issues agenda item then?

CHAIR ANDERSON: I guess so. I guess, yeah. We don't need that.

DR. ULSH: Okay.

CHAIR ANDERSON: Sorry. Or -- or if you got a question on it, then you can comment on it there rather than go through the preparation and then the review and approval of everything for a presentation, so let's leave that out.

DR. ULSH: I --

MEMBER CLAWSON: Andy, --

DR. ULSH: -- agree.

MEMBER CLAWSON: -- this is -- this is -- this is Brad. I just want to make sure that we -- we remember something. Being this a in-person meeting, be it whatever -- and I know we're hitting for 15, 20 minutes here and everything else like this, but also, too, we have an awful lot of new members that are coming onto the Board that I imagine that a lot of questions are now arising (audio drop) give enough time and have the ability to be able to bring forth some of these questions, like the -- the dedication to getting the dose reconstructions done, what we have been doing and everything like that. I just want to make sure that we give ourselves plenty

of time to do it because you -- you -- Andy, as well as anybody know, that when we get into these public settings like this, the discussions kind of seem to take on a different tone than what they usually do over the phone or whatever. And I just want to give us plenty of time to get to some of these questions that are out there. And -- and I -- I think (audio drop) to the public, but also some of the new board members that are coming in, too.

CHAIR ANDERSON: Does anyone else have comments? If you're talking, you're on mute.

Okay. Rashaun?

DR. ROBERTS: Okay. Yeah, thanks, everybody for your discussion and input into the August Board meeting agenda.

Andy, I don't have anything further.

CHAIR ANDERSON: Anyone else have any questions or comments? How about a motion to adjourn?

MEMBER FRANK: Motion to adjourn.

MEMBER BEACH: Second. This is Josie.

MEMBER FRANK: -- Frank making the motion.

CHAIR ANDERSON: Okay. Thank you very much. If anybody objects, speak up. If not, we're ready to adjourn and hopefully hear good news about August coming up. So, and you heard that --

MEMBER CLAWSON: (Indiscernible) --

CHAIR ANDERSON: -- we won't be -- go ahead.

MEMBER CLAWSON: Andy, I would just say one thing. For some of us, the -- the sooner we can go about it, the better, because like for me, I -- I fly out of a very small airport. And the sooner we can get anything, the better

for me. So, just -- just let us know one way or the other as soon as possible. Thank you.

CHAIR ANDERSON: And don't forget, we aren't going to be scheduling any -- any work groups or reviews going on in September. So, plan your vacation then. Okay. With that, we stand adjourned.

(Whereupon, the meeting was adjourned at 12:17 p.m. EDT.)